====== CanSino Biologics ======

{{ :pharmaceutical_companies:kxn-logo20220422en.png?200|}}

**CanSino Biologics**, or **CanSinoBio**, is a Chinese biotechnology company based in [[:china:Tianjin]], [[:China]].

===== History =====

==== COVID-19 ====

On May 12, 2020, the [[:National Research Council of Canada]] announced it would collaborate with CanSinoBio to advance the latter's [[:COVID-19 vaccines|COVID-19 vaccine]] candidate called [[:COVID-19 vaccines:Ad5-nCoV]].((National Research Council Canada. (2020, May 12). //The National Research Council of Canada and CanSino Biologics Inc. announce collaboration to advance vaccine against COVID-19.// Government of Canada. https://archive.ph/F0s1y)) [[:Lakshmi Krishnan]], director general of the NRC's Human Health Therapeutics Research Centre, said at the time that the trials in [[:Canada]] would complement and expand on what had been done in China.((Zafar, A. (2020, May 12). //Canadians to help develop, test potential COVID-19 vaccine from Chinese company.// CBC News. https://archive.ph/f85G2)) Testing on healthy human volunteers was to take place at the [[:Canadian Centre for Vaccinology]] (CCfV).

In August 2020, the collaboration fell apart amid rising tensions between the two countries.((Cooke, A. (2020, August 26). //Canadian COVID-19 clinical trial scrapped after China wouldn’t ship potential vaccine.// CBC News. https://archive.ph/gs4cQ)) According to the NRC, CanSino's state funding agencies (the [[:Beijing Institute of Technology]] and the [[:Ministry of Science and Technology of the People's Republic of China]]) had made changes to the collaboration agreement and had not authorized the shipment of vaccines to Canada. [[:Scott Halperin]], director of the Canadian Center for Vaccinology, later described the attempted partnership as "a waste of a lot of time".((Pinkerton, C. (2021, March 12). //“A waste of a lot of time”: Researcher in CanSino deal shares new details.// iPolitics. https://web.archive.org/web/20220712033648/https://ipolitics.ca/news/a-waste-of-a-lot-of-time-researcher-in-cansino-deal-shares-new-details))

===== Clinical trials =====

==== A Randomized, Double-blind, Placebo-controlled Phase II Clinical Trial to Evaluate the Safety and Immunogenicity of the Recombinant Novel Coronavirus Vaccine (Adenovirus Vector) in Healthy Adults Aged Above 18 Years ====

This is a phase II, randomised, double-blinded and placebo-controlled clinical trial in healthy adults above 18 years of age. This clinical trial is designed to evaluate the immunogenicity and safety of Ad5-nCoV which encodes for a full-length spike (S) protein of SARS-CoV-2.((//A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector) | Expanded Access Navigator.// Reagan-Udall Foundation for the FDA. Retrieved December 19, 2021, from https://navigator.reaganudall.org/clinical-trial/phase-ii-clinical-trial-evaluate-recombinant-vaccine-covid-19-adenovirus-vector))

The study is being run by Fengcai Zhu at the [[Jiangsu Province Centers of Disease Control and Prevention]] with the Insitute of Biotechnology, Academy of Military Medical Sciences, [[People's Liberation Army]] in the [[People's Republic of China]], in partnership with [[pharmaceutical_companies:CanSino Biologics]] Inc., Zhongnan Hospital, and [[Jiangsu Province Centers for Disease Control and Prevention]].((People's Liberation Army of China, CanSino Biologics Inc., Jiangsu Province Centers for Disease Control and Prevention, & Hubei Provincial Center for Disease Control and Prevention. (2020, May 18). //A Phase II Clinical Trial to Evaluate the Recombinant Vaccine for COVID-19 (Adenovirus Vector).// ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04341389))

The Lancet published results in August 2020 in a paper called "Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial".((Zhu, F.-C., Guan, X.-H., Li, Y.-H., Huang, J.-Y., Jiang, T., Hou, L.-H., Li, J.-X., Yang, B.-F., Wang, L., Wang, W.-J., Wu, S.-P., Wang, Z., Wu, X.-H., Xu, J.-J., Zhang, Z., Jia, S.-Y., Wang, B.-S., Hu, Y., Liu, J.-J., & Zhang, J. (2020). //Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.// The Lancet, 396(10249), 479–488. https://doi.org/10.1016/s0140-6736(20)31605-6))

===== External links =====

  * [[https://wiki.whiteroseintelligence.com/en/CanSino-Biologics|White Rose Wiki]]